SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Unichem Laboratories moves up on getting ANDA approval for Prasugrel Tablets

30 Aug 2023 Evaluate

Unichem Laboratories is currently trading at Rs. 418.25, up by 1.15 points or 0.28% from its previous closing of Rs. 417.10 on the BSE.

The scrip opened at Rs. 422.00 and has touched a high and low of Rs. 422.00 and Rs. 415.75 respectively. So far 1799 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 467.00 on 03-Nov-2022 and a 52 week low of Rs. 265.00 on 25-Jan-2023.

Last one week high and low of the scrip stood at Rs. 422.00 and Rs. 409.80 respectively. The current market cap of the company is Rs. 2944.72 crore.

The promoters holding in the company stood at 50.93%, while Institutions and Non-Institutions held 11.26% and 37.80% respectively.

Unichem Laboratories has received ANDA approval for its Prasugrel Tablets USP, 5 mg and 10 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Effient (Prasugrel) Tablets, 5 mg and 10 mg, of Cosette Pharmaceuticals, Inc.

Prasugrel tablets are indicated to reduce the rate of thrombotic CV events (including stent thrombosis) in patients with acute coronary syndrome. The product will be commercialized from Unichem’s Goa Plant.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company.

Unichem Lab Share Price

350.85 4.85 (1.40%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×